



18.07.2025		
12:15 - 13:15	Type: Industry Satellite symposium Title: Industry satellite symposium - slot 1	Grand Ballroom 1
12:15 - 13:15	Type: Industry Satellite symposium Title: Industry satellite symposium - slot 2	Grand Ballroom 4
13:15 - 13:45	Type: Break Title: Welcome reception	Foyer
13:45 - 14:10	Type: Opening session Title: Welcome to the ESMO Targeted Anticancer Therapies Asia Congress 2025 Moderation: Byoung Chul Cho, Republic of Korea; Yasushi Goto, Japan; Brigitte Ma, Hong Kong SAR, China	Grand Ballroom 1
13:45 - 13:55	Programme to be announced	
14:15 - 15:30	Type: Special session with Industry Title: Cell based therapies in oncology: Paths and challenges Moderation: Lin Shen, China	Grand Ballroom 1
14:15 - 14:30	The way forward for CART development in solid tumors: Industry perspective <u>Ezogelin Oflazoglu-Gruyters</u> , AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America	
14:30 - 14:45	Developing cell therapies for GI tumours in Asia <u>Lin Shen</u> , Peking University Cancer Hospital and Institute, Beijing, China	
14:45 - 15:00	Evolution of TIL therapy in solid tumors: Past, present, future <u>Martin Wermke</u> , Dresden University, Dresden, Germany	
15:00 - 15:30	Panel discussion and Q&A	
14:15 - 15:30	Type: Educational session Title: What did we learn from drug development in lung cancer? Moderation: Tony S.K. Mok, Hong Kong SAR, China	Grand Ballroom 4
14:15 - 14:30	Learning from identification and use of biomarkers in lung cancer <u>Siu Ching Li</u> , The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong SAR, China	
14:30 - 14:45	Learning from drug development and registration in China <u>Yi-Long Wu</u> , Guangdong Province People's Hospital, Guangzhou, China	
14:45 - 15:00	Learning from the evolution of master protocols for clinical trials in lung cancer <u>Ben Solomon</u> , Peter MacCallum Cancer Center, Melbourne, Australia	



15:00 - 15:15 **Challenges of combining new therapies with SoC in NSCLC**
Byoung Chul Cho, Yonsei University, Seoul, Republic of Korea

15:15 - 15:30 **Q&A and discussion**

15:45 - 17:25 **Type: Abstract session** **Grand Ballroom 1**
Title: Oral Abstract session 1

15:45 - 15:52 **230 - Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial**

Haoxin Peng, Peking University Cancer Hospital & Institute, Beijing, China

15:52 - 15:59 **240 - Target GP350 CAR-T cells therapy for Relapse/Refractory EBV-associated lymphoma**

Fan Wu, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

15:59 - 16:06 **360 - First-in-Human Phase 1 Study of a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager (TCE), BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma**

Jennifer Goldstein, Chao Family Comprehensive Cancer Center UCI Health, Orange, United States of America

16:06 - 16:18 **Invited Discussant abstracts 230, 240 and 360**

16:18 - 16:25 **370 - Phase 1a first-in-human study of neoantigen-like recombinant overlapping peptides (ROPs) therapeutic vaccine in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), ovarian cancer, and prostate cancer**

Wynne Wijaya, University of Oxford, Oxford, United Kingdom

16:25 - 16:32 **380 - Gut microbiome signatures of clinical response to pembrolizumab or pembrolizumab with chemotherapy in patients with treatment naïve, metastatic non-small cell lung cancer**

Jji Bum Lee, Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea

16:32 - 16:42 **Invited Discussant abstracts 370 and 380**

16:42 - 16:49 **870 - International consensus-driven recommendations for patient-reported outcome research objectives in early phase dose-finding oncology clinical trials: OPTIMISE-ROR**

Emily Alger, ICR - The Institute of Cancer Research - North Site, Sutton, United Kingdom

16:49 - 16:56 **880 - Improving Access to Clinical Trials and Novel Therapeutics for Advanced Solid Tumours in the Asia-Pacific Region: Insights from the ASTER Study**

Pankaj Panda, NCCS - National Cancer Centre Singapore, Singapore, Singapore



16:56 - 17:03 **1150 - PROPOSE: Predicting Phase 1 Trial Fitness Using Patient-Reported Outcomes and a Clinician-Completed Prognostic Index.**

Sathya Manoharan, Peter MacCallum Cancer Center, Melbourne, Australia

17:03 - 17:15 **Invited Discussant abstracts 870, 880 and 1150**

17:15 - 17:25 **Q&A**

17:30 - 18:30 **Type: Poster Display** **Foyer**
Title: Cocktail & Poster Display session

17:30 - 17:30 **3P - Pharmacokinetic (PK) evaluation of tisotumab vedotin (TV) in Chinese patients (pts) with advanced solid tumors**

Rutie Yin, West China Second University Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China

17:30 - 17:30 **4P - Targeting IL1RAP by ADCs in distinct oncofusion-driven cancers**

Haifeng Zhang, BC Cancer Agency - Vancouver, Vancouver, Canada

17:30 - 17:30 **5P - Construction of Efficacy Prediction Model for T-DXd Treatment of HER2-positive and HER2-negative Breast Cancer Based on Hematological Indicators: A Real-world Study**

Yanfang Su, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China

17:30 - 17:30 **6P - Real-world outcomes of trastuzumab deruxtecan in HER2-low metastatic breast cancer: A single center retrospective analysis**

Raja Chhabra, BLK-Max Super Speciality Hospital, New Delhi, India

17:30 - 17:30 **7P - Real-World Efficacy and Safety of Trastuzumab Emtansine Biosimilar in HER2-Positive Breast Cancer: A Retrospective Observational Study in Indian Patients**

Naveen K, Tata Memorial Hospital, Mumbai, India

17:30 - 17:30 **8P - Next generation Topoisomerase I inhibitors as novel ADC payloads to overcome resistance to ADC with Camptothecin-Based payloads**

Qun Dang, Henan Genuine Biotech Limited Co., Ltd., Shanghai, China

17:30 - 17:30 **9P - Total neoadjuvant therapy with trastuzumab in HER2 positive gastric and gastroesophageal junction adenocarcinoma: interim analysis results**

Rukiyat Abdulaeva, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation

17:30 - 17:30 **10P - Therapeutic approaches and outcomes in Russian patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic gastric and/or gastroesophageal junction (GEJ) adenocarcinoma**

Rukiyat Abdulaeva, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation



- 17:30 - 17:30 **11P - Molecular testing and monoclonal antibody utilization patterns and outcomes in advanced colorectal cancers in India - a multi-institutional Real World Study**
Vivek Agarwala, Narayana Superspeciality Hospital - Howrah, Howrah, India
- 17:30 - 17:30 **12P - Comparative Evaluation of Clinical Response to First-Line Chemotherapy With or Without Bevacizumab in Advanced Ovarian Cancer: An Ambispective Single-Center Study in India.**
Harpreet Angural, Max Super Speciality Hospital - Patparganj, New Delhi, India
- 17:30 - 17:30 **13P - A novel KRASG12V-targeted bispecific T-cell engager promotes immunity against colorectal solid tumor**
Thanh Nhan Huynh, Gene Solutions Vietnam, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **14eP - Sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in Chinese patients (pts) with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC): sub analysis of the results from the phase 3 EVER-132-002 study**
Shusen Wang, Sun Yat-sen University Cancer Center, Guangzhou, China
- 17:30 - 17:30 **15eP - An Observational Study on the Efficacy and Safety of TROP2-Targeted Antibody-Drug Conjugates as a Neoadjuvant Therapy for Early-Stage HER2-Negative Breast Cancer**
Yongqi Ren, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- 17:30 - 17:30 **16eP - Efficacy and Safety of Bevacizumab Biosimilar in the Treatment of Brain Metastases from Breast Cancer: A Prospective, Single-Arm, Multicenter, Real-World Study**
Gang Li, Minhang Branch of Fudan University Affiliated Cancer Hospital, Shanghai, China
- 17:30 - 17:30 **17eP - Efficacy of cetuximab-based vs pembrolizumab-based therapy in first-line treatment of recurrent and metastatic head and neck cancer with low PD-L1 expression.**
Margarita Nosova, Oncology center No.1 City Clinical Hospital n.a. S.S.Yudin, Moscow, Russian Federation
- 17:30 - 17:30 **18P - Integrating Real-Time Artificial Intelligence (ChatGPT) into Oncology Case Discussions: An Innovative Educational Model to Enhance Clinical Reasoning**
Diogo Ribas, Universidade Estadual De Goiás, Goiânia, Brazil
- 17:30 - 17:30 **19P - Developing a multi-lingual clinical trial matching platform by large language models in the Hong Kong Special Administrative Region**
Yikang Steven Huang, Codex Genetics Limited, Hong Kong, Hong Kong SAR, China
- 17:30 - 17:30 **20P - Prospective pilot study of AI-assisted clinical trial matching system**
Viviana Oo, NCCS - National Cancer Centre Singapore, Singapore, Singapore



- 17:30 - 17:30 **21P - Evaluating the Accuracy and Reliability of AI Language Models in Chemotherapy Patient Education: A Comparative Analysis of ChatGPT, Gemini, DeepSeek, Grok, and Copilot**
Mohamed El-Mezayen, Alexandria Faculty of Medicine, Alexandria, Egypt
- 17:30 - 17:30 **22P - PiIPal.ai: Using Artificial Intelligence to Improve Adherence to Oral Chemotherapy, TKIs, and CDK4/6 Inhibitors — A Pilot Study from a Tertiary Cancer Center in India**
Kavi Mg, Sri Ramachandra Higher Education and Research Center, Chennai, India
- 17:30 - 17:30 **25P - Cancer-specific NK ligand signatures could predict tumor responsiveness to allogenic NK cell therapy**
Nam Tran, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **26P - Can dual specific CAR NK cells enhance solid tumor targeting?**
Fahmida Islam, Monash University - Faculty of Medicine, Nursing and Health Sciences, Clayton, Australia
- 17:30 - 17:30 **27P - CAR T Cells Secreting Tumour-Specific Bispecific Engagers for Solid Tumour Treatment**
Yu-Kuan Huang, Peter MacCallum Cancer Center, Melbourne, Australia
- 17:30 - 17:30 **28P - Pre-clinical development of CAR-T cells targeting a lytic EBV antigen gp350 for therapy of EBV-positive diffuse large B-cell lymphoma**
Li Yan-Li, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China
- 17:30 - 17:30 **29eP - Efficacy of Combination Therapy with Olaparib and Pembrolizumab in BRCA-Mutated Ovarian Cancer**
Ju'An Yang, XINQIAO HOSPITAL OF AMU, Chongqing, China
- 17:30 - 17:30 **30eP - MIF-Mediated Cell Competition Between Lung Adenocarcinoma and Alveolar Type II Cells Promotes Radiation Resistance**
Hongxia Cheng, Tongji University - Jiading Campus, Shanghai, China
- 17:30 - 17:30 **31P - Niraparib versus fluzoparib for first-line maintenance treatment of newly diagnosed advanced ovarian cancer: a network meta-analysis**
Lei Yang, The first hospital of Jilin University, Changchun, China
- 17:30 - 17:30 **32P - Pathogenic Germline Variants in Breast Cancer Patients Associated with Different HER2 Expression Levels**
Ning Liao, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- 17:30 - 17:30 **33P - SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer**
Yong Wha Moon, CHA Bundang Medical Center, Seongnam, Republic of Korea



- 17:30 - 17:30 **34P - AARS1-Mediated Lactylation of ELK4 Promotes NHEJ-Dependent DNA Repair and Confers Radioresistance in Colorectal Cancer**
Zhehui Zhu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
- 17:30 - 17:30 **35P - Research on the Impact of LSM11 on Radiotherapy in Hepatocellular Carcinoma Cells**
Wenyi Jiang, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China
- 17:30 - 17:30 **40P - Phase 2 Trial of the PD-1 Inhibitor Sintilimab in Recurrent or Progressive Meningioma**
Yali Wang, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 17:30 - 17:30 **41P - Immunocheckpoint inhibitors versus chemotherapy with brain radiation for patients with brain metastases from non-small cell lung cancer**
Sharmin Talukder, Combined military hospital, Dhaka, Bangladesh
- 17:30 - 17:30 **42P - Real-world comparative study of low versus standard dose Nivolumab in 2nd-line treatment of Advanced Non-Small Cell Lung Cancer**
Vivek Agarwala, Narayana Superspeciality Hospital - Howrah, Howrah, India
- 17:30 - 17:30 **43P - AGTR1 inhibition enhances the effectiveness of chemo-immunotherapy in non-squamous non-small cell lung cancer**
Tatsuki Ikoma, Kansai Medical University, Hirakata, Japan
- 17:30 - 17:30 **44P - Combination Therapy with Immune Checkpoint Inhibitors and Chemotherapy Improves Survival in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Network Meta-Analysis**
Ahmed Ibrahim, Alexandria University, Alexandria, Egypt
- 17:30 - 17:30 **45P - Low-Dose Immunotherapy 6weekly plus Triple Metronomic Chemotherapy in Advanced Head and Neck Cancer-A prospective, Open Label Single Centre Study from Eastern India**
Santosh Swain, IMS & SUM Hospital, Bhubaneswar, India
- 17:30 - 17:30 **46P - Immune-related Adverse Events (irAEs) among Cancers of the Lip, Oral Cavity and Pharynx (CLOP) patients receiving PD-1 inhibitors.**
Satheesh Kumar Poolakkad Sankaran, University at Buffalo - Jacobs School Of Medicine and Biomedical Sciences, Buffalo, United States of America
- 17:30 - 17:30 **47P - Cell surface SRRM2 is a new biomarker of poor prognosis and a molecular target for the immunotherapy of AML**
Wangju Zhang, The Second Affiliated Hospital of Anhui Medical University, Hefei, China



- 17:30 - 17:30 **48P - Molecular Correlates of Clinical Response to Combination Immunotherapy in Advanced Fumarate Hydratase Deficient Renal Cell Carcinoma**
Yunze Xu, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 17:30 - 17:30 **49P - Dietary Carbohydrate Intake Shapes Gut Microbial Features Associated with Immune Checkpoint Inhibitor (ICI) Outcomes in Hepatocellular (HCC) and Cholangiocarcinoma (CCA) patients**
Joycelyn Lee, National Cancer Centre Singapore, Singapore, Singapore
- 17:30 - 17:30 **50P - Neutrophil-Driven T-Cell Exhaustion via SELL-SELPLG and TYROBP-CD44 Axes in AFGC: Depletion Reverses PD-1 Resistance through Cytokine Reprogramming**
Jialin Lu, Peking University Cancer Hospital & Institute, Beijing, China
- 17:30 - 17:30 **51P - Exploration of Immune-Tumor Interactions in Gastric Tumors: Bioinformatics Analysis of Immune-Response Gene Networks and Identification of Potential Immunotherapy Targets**
Adicitra Bestari, Muhammadiyah Surabaya University, Surabaya, Indonesia
- 17:30 - 17:30 **52P - Comprehensive Tumor Profiling and Biomodeling-Guided Discovery of Shared Neoantigens for Off-the-Shelf Vaccines in Colorectal Cancers in Asia**
Diem Tran, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **53P - Exploiting Fusion-Derived Neoantigens for Adjuvant Therapy in Colorectal Cancer**
Tran Nguyen, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **54P - epiTCR-CLFP: Empowering personalized cancer vaccines through AI-enabled neoantigen and TCR matching**
My-Diem Nguyen Pham, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **55P - Integrating Patient TCR Repertoires for Precision Neoantigen Selection and Prioritization in Personalized Cancer Vaccines**
Tran Nguyen, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **56P - Bioengineered Nanovaccine with a TLR7/8 Agonist for Needle-Free Intranasal Immunotherapy of Metastatic Cancer**
Byungdeok Kim, SKKU - Sungkyunkwan University - Natural Sciences Campus, Suwon, Republic of Korea
- 17:30 - 17:30 **57P - Exploring the Therapeutic Potential of Withania somnifera Stem Extract in Breast Cancer: Modulation of EMT, MET, Tumor-Stroma Interactions and Implications for Enhancing Immunotherapy Response Using a 3D Co-Culture Model**
Aditi Srivastava, Era's Lucknow Medical College & Hospital, Lucknow, India



- 17:30 - 17:30 **58P - Microneedle-assisted lymphatic delivery of a natural immune modulator for enhanced cancer immunotherapy**
Su Yeon Lim, SKKU - Sungkyunkwan University - Natural Sciences Campus, Suwon, Republic of Korea
- 17:30 - 17:30 **59P - Complement system in primary uveal melanoma**
Iryna Zherka, University of Oxford, Oxford, United Kingdom
- 17:30 - 17:30 **60P - Antitumor Effect of Near-Infrared Light Activated TLR7/8 Targeted Theranostic Nanovaccine for Effective Photothermal Immunotherapy**
Vivek Raju, Bharathiar University, Coimbatore, India
- 17:30 - 17:30 **61P - Improving Neoantigen Prediction Using Long Immunogenic Peptides**
Kim-Cuong Ho, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **62P - SIRPA as a Novel Target for Immunotherapy in NSCLC**
Yongqi Kang, Guangxi Medical University, Nanning, China
- 17:30 - 17:30 **63eP - Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors at Hanoi Oncology Hospital, Vietnam**
Thao Ninh, Hanoi Oncology Hospital, Hanoi, Vietnam
- 17:30 - 17:30 **64eP - Comparative Toxicity Profiles of PD-1 and PD-L1 Inhibitors Across Treatment Lines in NSCLC: A Systematic Review and Meta-Analysis**
Bara Hammadeh, Al-Balqa Applied University, As-Salt, Jordan
- 17:30 - 17:30 **65eP - Real-World Impact of Pembrolizumab Plus Lenvatinib in Metastatic Uveal Melanoma: A Retrospective Multicenter Study**
Zakhra Magomedova, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 17:30 - 17:30 **66eP - Survival and Safety Analysis of Adebrelimab Combined with Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer in Real-World Settings**
Li Yu, Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang, China
- 17:30 - 17:30 **67eP - A 3D Model for Validating Novel TCR-T Therapy (TP53-R273H)**
Nguyen Quan, Gene Solutions Joint Stock Company, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **68eP - Dual Biomarker Profiling in Prostate Cancer: Circulating lncRNAs and Blood-Based Immune Markers Reveal Diagnostic and Immunological Stratification Potential**
Poornima Verma, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- 17:30 - 17:30 **70P - Impact of US FDA Project Optimus on the number of patients and cohorts in First-In-Human phase 1 small molecule inhibitor trials in NSCLC**
Zhaohui Arter, UCI Health - University of California Irvine, Orange, United States of America



- 17:30 - 17:30 **71P - Under reporting of mean and median relative dose intensity in phase 2 and 3 clinical trials of tyrosine kinase inhibitors and small molecular inhibitors in NSCLC.**
Cathleen Park, UC Irvine Medical Center, Orange, United States of America
- 17:30 - 17:30 **72P - Selecting optimal first-line treatment strategy for advanced-stage EGFRm+ NSCLC patients: a network meta-analysis**
Gengda Huang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 17:30 - 17:30 **73P - Negative Regulation of Cell Adhesion as a Driver of Brain Metastasis in NSCLC Patients with EGFR Amplification**
Hainan Yang, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 17:30 - 17:30 **74P - Evaluation of the Clinical Significance of Rare Epidermal Growth Factor Receptor Exon 19 Insertion-Deletion Variants on Tyrosine Kinase Inhibitor Efficacy in Non-Small Cell Lung Cancer: A Five-Year Update**
Xu Jinhe, Fujian Medical University, Fuzhou, China
- 17:30 - 17:30 **75P - Multimodal navigational responders targeting tumor cell-intrinsic RRM2 to overcome EGFR-TKIs resistance and induce intratumoral immune reprogramming in lung cancer**
Jinyu Zhu, Peking University, Beijing, China
- 17:30 - 17:30 **76P - Tyrosine Kinase Inhibitors (TKIs) in EGFR Exon 20 Insertions: A Systematic Review and Meta-Analysis**
Hashim Talib Hashim, University of Warith Al-Anbiyaa, College of Medicine, Karbala, Iraq
- 17:30 - 17:30 **77P - PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase 1 trial**
Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia
- 17:30 - 17:30 **78P - Detrimental Impact of Gastric Acid Suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors Efficacy: Evidence from a Systematic Review and Meta-Analysis**
Jiefeng Luo, Fudan University Affiliated Cancer Hospital, Shanghai, China
- 17:30 - 17:30 **79P - Combination of PARP Inhibitor and CDK4/6 Inhibitor in Breast Cancer: A Systematic Review of In Vivo and In Vitro Studies**
Andree Kurniawan, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, Indonesia
- 17:30 - 17:30 **80P - Targeting SAT1-mediated polyamine metabolism and ferroptosis to enhance the efficacy of targeted therapy in KRAS-mutant cancer with differential KEAP1 status**
Yunyi Bian, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China



- 17:30 - 17:30 **81P - Targeting the PIK3CA/c-MYC Pathway to inhibit Oncogenicity and Stemness in Cervical Cancer**
Rupa Mishra, Amity University, Noida, India
- 17:30 - 17:30 **82P - Y220C, a Rare but Druggable TP53 Mutation: A Molecular Landscape in an Australian Context**
Gregory Gaughran, Omico/UNSW, Sydney, Australia
- 17:30 - 17:30 **83P - Efficacy and Safety of KRAS G12C Inhibitors Across Solid Tumors: A Systematic Review and Meta-Analysis**
Hashim Talib Hashim, University of Warith Al-Anbiyaa, College of Medicine, Karbala, Iraq
- 17:30 - 17:30 **84P - Investigating Pyruvate Dehydrogenase Kinase 3 Inhibitory Potential of Myricetin Using Integrated Computational and Spectroscopic Approaches**
Anas Shamsi, Ajman University, Ajman, United Arab Emirates
- 17:30 - 17:30 **85eP - CDK4/6 and CDK8 Co-Inhibition Drives Immune-Mediated Tumour Suppression in Acute Myeloid Leukaemia**
Ramin Hassankhani, UniSA - University of South Australia, Adelaide, Australia
- 17:30 - 17:30 **86eP - Therapeutic Role of Hippo Signaling Pathway and Yes-Associated Protein in Overcoming Glioblastoma Temozolomide Chemoresistance**
Cheuk Lun Wong, The University of Hong Kong - Queen Mary Hospital, Hong Kong, Hong Kong SAR, China
- 17:30 - 17:30 **90P - Integrating AI-based prediction tools with bulk TCR sequencing enables rapid and cost-effective identification of TCR clones for personalized TCR-T therapy**
Quynh Pham, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **91eP - Investigation of the Effect of Chemotherapy-Induced Autophagic Secretome on the Anti-Tumor Response of Peripheral Blood Natural Killer Cells**
Ayfer Karlitepe, Aydin Adnan Menderes University, Aydın, Türkiye
- 17:30 - 17:30 **95P - Integrating plasma ctDNA detection and tumor comprehensive genomic and transcriptomic profiling to maximize the clinical implications of precision oncology**
Phuc Nguyen, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **96P - Direct comparison of tumor-informed and tumor-agnostic ctDNA assays in non-small cell lung cancer**
Van-Anh Nguyen, Medical Genetics Institute, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **97P - Molecular Profiling of Metastatic Non Small Cell Lung Carcinoma- Real World Analysis from a Tertiary Care Center in India**
Sreedhar Cherulil, Aster MIMS Hospital, Kozhikode, India



- 17:30 - 17:30 **98P - Comprehensive Molecular Profiling of Combined Hepatocellular Carcinoma and Cholangiocarcinoma reveals Distinct Notch Signaling Subgroups with Prognostic Significance**
Seokhwi Kim, Ajou University School of Medicine, Suwon, Republic of Korea
- 17:30 - 17:30 **99P - Pre-analytical barriers to successful molecular profiling**
Christine Carolyn, National Cancer Centre Singapore, Singapore, Singapore
- 17:30 - 17:30 **100P - Comprehensive genomic landscape of Asian and African breast cancer (BC) patients (pts)**
Valerie Heong, Tan Tock Seng Hospital, singapore, Singapore
- 17:30 - 17:30 **101P - Impact of co-mutations in metastatic CRC with KRAS mutations**
Vijay Srinivasalu, SPARSH Super Specialty Hospital, Bangalore, India
- 17:30 - 17:30 **102P - Lipid nanoparticle-delivered IFN α 2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis**
Kebin Liu, MCG - Medical College of Georgia - Augusta University, Augusta, United States of America
- 17:30 - 17:30 **103P - Comprehensive ¹H-NMR Tissue Metabolomics and Pathway Analysis for Biomarker Discovery in Renal Cell Carcinoma**
Shivani Kumari, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- 17:30 - 17:30 **104P - ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Metabolic Reprogramming**
Xinyue Ma, Qilu Hospital of Shandong University, Jinan, China
- 17:30 - 17:30 **105P - hnRNPA1 Promotes CD8+ T Cell Exhaustion via Antagonizing TRM21-mediated CD155 Ubiquitination and Degradation in Head and Neck Squamous Cell Carcinoma**
Lu Zhang, Affiliated Cancer Hospital of Chongqing University, Chongqing, China
- 17:30 - 17:30 **106P - Building an Asian Patient-Derived Organoid Biobank for Precision Oncology**
Thong Dang, Genesolutions, Ho Chi Minh City, Vietnam
- 17:30 - 17:30 **107P - Identification of novel targets in residual triple-negative breast cancer post-neoadjuvant chemoimmunotherapy to personalise adjuvant treatment**
Atul Batra, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 17:30 - 17:30 **108P - Urinary microRNA Expression Signatures as Non-Invasive Biomarkers for Predicting Bladder Cancer Progression**
Malika Ranjan, Amity University, Noida, India
- 17:30 - 17:30 **109P - Spatially resolved chromosomal aberrations are sensitive towards targeted therapy against proliferation and DNA damage response**
Ioanna Tsea, Karolinska Institute, Solna, Sweden



- 17:30 - 17:30 **110P - METTL3-Mediated m6A Modification of circDNAH14 Promotes Non-Small Cell Lung Cancer Progression**
Shiyi Qin, Affiliated Hospital of Nantong University, Nantong, China
- 17:30 - 17:30 **111P - HER2 Overexpression Drives Drug-Tolerant Persisters to First-Line Amivantamab and Lazertinib in EGFR-Mutant Non-Small Cell Lung Cancer**
Joo Sung Shim, Severance Hospital - Yonsei University College of Medicine, Seoul, Republic of Korea
- 17:30 - 17:30 **112eP - Prevalence of Oesophageal squamous cell carcinoma (ESCC) associated MTR and MTHFR gene polymorphism and its synergistic association with alcohol in pathogenesis of ESCC.**
Rohit Mahajan, AIIMS - All India Institute of Medical Sciences, Bathinda, Bathinda, India
- 17:30 - 17:30 **113eP - H3K27me3 is a potential biomarker for negative prognosis and low OS in NSCLC**
Nikolay Evgeniev, Complex Oncology Centre-Ruse, Ruse, Bulgaria
- 17:30 - 17:30 **114eP - FOLFOX-Induced Extracellular Vesicles Express HSP70 and Promote Dendritic Cell Maturation via TLR2/4 Signaling for Enhanced Anti-Tumor Immunity**
Lim Chai Ling, UKM - Universiti Kebangsaan Malaysia - Faculty of Medicine, Cheras, Malaysia
- 17:30 - 17:30 **116P - Development of an Injectable Thermal-Responsive Brachytherapy Seed for Advanced Solid Tumor Treatment**
Wenge Liu, Zonsen PepLib Biotech Inc., Zhuzhou, China
- 17:30 - 17:30 **117P - Development of small molecule inhibitor of Adenosine deaminase acting on RNA (ADAR1) for the treatment of oral squamous cell carcinoma**
Pei San Yee, Cancer Research Malaysia, Subang Jaya, Malaysia
- 17:30 - 17:30 **118P - Impact of Age and Comorbidity on Safety Outcomes in Phase 1 Trials Participants for Metastatic Solid Malignancies**
Sathya Manoharan, Peter MacCallum Cancer Center, Melbourne, Australia
- 17:30 - 17:30 **119P - A Randomized, Open Label ,Phase 2 RCT on the use of short-term, combination pharmacotherapy in improving tolerance to cytotoxic chemotherapy and chemo-radiotherapy in patients with solid cancers**
Smitha Saldanha, Kidwai Memorial Institute of Oncology, Bangalore, India
- 17:30 - 17:30 **120P - Mechanistic Study on the Inhibition of Cervical Cancer by Polyphyllin VI via Modulating TRPC4/Gnrh**
Li-Xuan Wang, Yunnan University of Traditional Chinese Medicine, Kunming, China
- 17:30 - 17:30 **121P - CK1ε modulates CD8+ T cell infiltration by acting on vascular endothelial cell structure via ACTA1.**
Vivian Weiwen Xue, Shenzhen Technology University, Shenzhen, China



- 17:30 - 17:30 **122P - In silico analysis of Cleistanthin A and derivatives as potential Topoisomerase II inhibitor**
Bunnatut Panasawatwong, Mahidol University - Phayathai Campus, Bangkok, Thailand
- 17:30 - 17:30 **123P - Efficacy & Value of Targeted Radionuclide Therapy with 177-Lutecium-PSMA-In Metastatic Castration-Resistant Prostate Cancer.**
Karan Peepre, Mahatma Medical College,Hospital & University of Medical Sciences & technology,Jaipur,Rajasthan,India, Jaipur, India
- 17:30 - 17:30 **124P - Melittin Inhibits the Growth of Hepatocellular Carcinoma Huh7 Cells by Downregulating LARS2 and ZNF19**
Hui Ye, Shanghai Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 17:30 - 17:30 **125P - Role of 2-deoxy-2-[18F]fluoro-D-glucose & Positron Emission Tomography FDG/PET-CT Imaging In the Staging (Diagnosis), and Evaluation of response to Targeted Treatment of Lung Cancer.**
Karan Peepre, Mahatma Gandhi Medical College,Hospital & University of Medical Sciences & Technology,Jaipur,Rajasthan,India, Jaipur, India
- 17:30 - 17:30 **126P - Improving treatment methods for immature teratoma ovaries in children and adolescence**
Anvar Shukullaev, Pediatric Hematology, Oncology and Clinical Immunology Center, Tashkent, Uzbekistan
- 17:30 - 17:30 **127P - A Multicenter Real-World Efficacy Evaluation Study of Oral Chinese Herbal Medicine for Advanced Colorectal Cancer**
Rui Li, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
- 17:30 - 17:30 **128P - TROP2 drives colorectal cancer liver metastasis through activating YBX1-HIF1A pathway and glycolysis**
Weifeng Wang, Sun Yat-Sen University Cancer Center, Guangzhou, China
- 17:30 - 17:30 **129P - Supramolecular Assembly-Enabled Cancer Theranostics through Concurrent Ferroptosis-Apoptosis**
Meng Wei, Northwestern Polytechnical University - Youyi campus, Xi'an, China
- 17:30 - 17:30 **130P - Inhibition of VGCC and BKCa Channels by Trimebutine Maleate Suppresses Stemness and Drug Resistance in Ovarian Cancer Stem Cells**
Woo Somin, KNU - Kyungpook National University, Daegu, Republic of Korea
- 17:30 - 17:30 **131eP - Phosphate-functionalized carbon nanomaterials inhibits metastasis by downregulating PI3K-Akt in triple-negative breast cancer**
Sehresh Saleem, National Taiwan Ocean University, Keelung City, Taiwan



- 17:30 - 17:30 **132eP - Clinicopathological Features and Treatment Strategies for Metaplastic Breast Carcinoma in Vietnam - A multicenter study**
Trinh Nguyen, VinUniversity, Hanoi, Vietnam
- 17:30 - 17:30 **133eP - MRI-Targeted Transperineal Versus Transrectal Biopsy for Prostate Cancer Detection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.**
Bilal Aslam, University of Lahore - Defence Road Campus, Lahore, Pakistan
- 17:30 - 17:30 **134eP - Electrophysiological criteria of cardiotoxicity in patients with hepatocellular carcinoma**
Dinara Bayanova, Medical University Astana, Nur-Sultan, Kazakhstan
- 17:30 - 17:30 **135eP - Synergistic Approach in Metastatic Esophageal Carcinoma: FOLFOX, Pembrolizumab, and Zolbetuximab Yield Remarkable Response in PD-L1 and Claudin-1 Positive Patients.**
Jasneet Gill, Gandhi Medical College, Bhopal, India
- 17:30 - 17:30 **136eP - Resectability of colorectal liver metastases according to RAS and BRAF-mutational status: a single-center retrospective study**
George Makiev, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 17:30 - 17:30 **137eP - Survival Benefits of Ma Recipe: An Herbal Remedy for Advanced Progressive Solid Tumor – A Retrospective Case Series**
Jiangnan Feng, Tongrun Tang TCM Clinics, Wuhan, China



19.07.2025

08:30 - 09:45 **Type: Educational session** **Grand Ballroom 1**
Title: Reporting clinical trials in the era of precision oncology: Important considerations
Moderation: Herbert Ho Fung Loong, Hong Kong SAR, China

08:30 - 08:45 **How to report subgroup analyses in randomised clinical trials: Exploratory or a priori?**
Annie Wong, Te Whatu Ora-Capital, Coast and Hutt Valley, Wellington, New Zealand

08:45 - 09:00 **Reporting exploratory biomarker analyses in early phase clinical trials: Pitfalls and precautions**
Aya El-Helali, HKU - The University of Hong Kong, Hong Kong, Hong Kong SAR, China

09:00 - 09:15 **Incorporating patient reported outcome measurements in early phase clinical trials**
Herbert Ho Fung Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China

09:15 - 09:30 **Volcanos, spiders, heatmaps: Illustrating complex genomic/clinical correlative data in translational research publications using head & neck cancer as an example**
Darren Wan-Teck Lim, NCCS - National Cancer Centre Singapore, Singapore, Singapore

09:30 - 09:45 **Q&A and discussion**

08:30 - 09:45 **Type: Educational session** **Grand Ballroom 4**
Title: Science and statistics: Informing novel phase I trial designs in oncology
Moderation: Chia-Chi Lin, Taiwan; Toshio Shimizu, Japan

08:30 - 08:45 **Novel trial designs for phase I clinical trials: Limitations and future opportunities**
Chia-Chi Lin, NTUH - National Taiwan University Hospital, Taipei City, Taiwan

08:45 - 09:00 **Assessing efficacy in novel phase I trials: Scientific perspectives**
Toshio Shimizu, Kansai Medical University Hospital, Hirakata, Japan

09:00 - 09:15 **Breakthroughs and innovative approaches in the statistical methodology of phase I trials**
Christina Yap, ICR - The Institute of Cancer Research - North Site, Sutton, United Kingdom

09:15 - 09:30 **Patient accrual in novel phase I trials: What would be the ultimate platforms?**
Timothy Anthony Yap, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America

09:30 - 09:45 **Q&A and discussion**



09:45 - 10:15	Type: Break Title: Coffee break	Foyer
10:15 - 11:30	Type: Special session with Industry Title: Fast tracking drug development by early screening for tumour agnostic potential: Trialist, sponsor and regulator views Moderation: Janice Wing-Hang Tsang, Hong Kong SAR, China	Grand Ballroom 1
10:15 - 10:30	How to screen for tumour agnostic potential and frame a drug development plan: In the industry perspective <u>Ron Fleming</u> , Daiichi Sankyo, Inc., Basking Ridge, United States of America	
10:30 - 10:45	How to accelerate pan-tumour drug development: The academic perspective <u>Brigitte Ma</u> , The Chinese University of Hong Kong - Sino Building, Hong Kong, Hong Kong SAR, China	
10:45 - 11:00	Issues and perspectives for tumour agnostic drug development: The regulator views <u>Emi Noguchi</u> , Pharmaceuticals and Medical Devices Agency, Chiyoda-ku, Japan	
11:00 - 11:30	Panel discussion and Q&A	
10:15 - 11:30	Type: Educational session Title: How to develop the next generation anti-cancer biologics Moderation: Elizabeth Smyth, United Kingdom	Grand Ballroom 4
10:15 - 10:30	Immunomodulatory antibody drug engineering <u>Sergio Quezada</u> , UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom	
10:30 - 10:45	Using immuno-biologics and cytokines to enhance T cell responses <u>Sophia Yien Ning Wong</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
10:45 - 11:00	Prioritising targets and design of TCR-T therapy in solid tumors <u>Anthony Tanoto Tan</u> , Duke-NUS Graduate Medical School, Singapore, Singapore	
11:00 - 11:15	Enhancing BiTEs in haematological malignancies <u>Yunxin Chen</u> , SGH - Singapore General Hospital, Singapore, Singapore	
11:15 - 11:30	Q&A and discussion	
11:35 - 12:05	Type: Keynote address Title: Global development of phase I developmental therapeutics: An odyssey through recent decades Moderation: Andres Cervantes, Spain	Grand Ballroom 1
11:35 - 11:40	Introduction to the Keynote Speaker <u>Andres Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, Spain	



11:40 - 12:05 **Global development of phase I developmental therapeutics: An odyssey through recent decades**

Lillian Siu, Princess Margaret Cancer Centre, Toronto, Canada

12:05 - 12:45 **Type: Break** **Foyer**
Title: Lunch

12:45 - 13:45 **Type: Industry Satellite symposium** **Grand Ballroom 1**
Title: Roche - New horizons and future directions in targeted therapies for breast cancer
Moderation: Janice Wing-Hang Tsang, Hong Kong SAR, China

12:45 - 12:50 **Introduction**
Janice Wing-Hang Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, Hong Kong SAR, China

12:50 - 13:20 **Next-generation targeted therapies in breast cancer: Innovative approaches and future perspectives**
Rupert Bartsch, Medizinische Universitaet Wien, Vienna, Austria

13:20 - 13:35 **Harnessing innovation through collaboration: The strategic role of partnering in advancing healthcare solutions**
Kyle Chen, F. Hoffmann-La Roche Ltd, Shanghai, China

13:35 - 13:45 **Panel discussion**

12:45 - 13:45 **Type: Industry Satellite symposium** **Grand Ballroom 4**
Title: MSD - From hot to cold, from metastatic to early stage: Transforming tumour responses in immunotherapy

12:45 - 12:55 **Understanding tumour micro-environment**

12:55 - 13:15 **Immunotherapy clinical development: i) From hot tumour to cold tumour; ii) From metastatic stage to early stage**

13:15 - 13:35 **Improving survival in TNBC and NSCLC with immunotherapy and novel agents**
Rina Hui, The University of Hong Kong - Queen Mary Hospital, Hong Kong, Hong Kong SAR, China

13:35 - 13:45 **Panel discussion with audience and Q&A**



14:00 - 15:15	Type: Special session with Industry Title: Targeted therapies, biomarkers and combination approaches in drug development: Dose optimisation in the continuum of clinical research Moderation: Do-Youn Oh, Republic of Korea; Dongmei Zhang, China	Grand Ballroom 1
14:00 - 14:15	Implementing dose optimisation: Essentials and challenges <u>Do-Youn Oh</u> , Seoul National University Hospital, Seoul, Republic of Korea	
14:15 - 14:30	Biomarker-based and model-informed dose optimisation of targeted monotherapies <u>Dongmei Zhang</u> , Takeda (China) Holdings Co., Ltd., Shanghai, China	
14:30 - 14:45	Dose optimisation during the development of novel combinations <u>Jia Jenny Liu</u> , St Vincent's Hospital Sydney, Darlinghurst, Australia	
14:45 - 15:15	Panel discussion and Q&A	
14:00 - 15:15	Type: Educational session Title: Artificial intelligence in drug development: Current applications and research Moderation: Xiaole Shirley Liu, United States of America	Grand Ballroom 4
14:00 - 14:20	Applications of AI in oncology drug trials <u>Kee Yuan Ngiam</u> , NUH - National University Hospital (S) Pte. Ltd., Singapore, Singapore	
14:20 - 14:40	Artificial intelligence in small molecule drug discovery <u>Feng Ren</u> , Insilico Medicine Shanghai Ltd., Shanghai, China	
14:40 - 15:00	Artificial intelligence in biologics drug discovery <u>Xiaole Shirley Liu</u> , GV20 Therapeutics, Cambridge, United States of America	
15:00 - 15:15	Q&A and discussion	
15:15 - 15:45	Type: Break Title: Coffee break	Foyer
15:45 - 17:25	Type: Abstract session Title: Oral Abstract session 2	Grand Ballroom 1
15:45 - 15:52	890 - INSPIRE study – Innovating access to Novel therapies through Standardized Prospective Integration of Response Evaluations <u>Aaron Tan</u> , National Cancer Centre Singapore, Singapore, Singapore	
15:52 - 15:59	920 - Clinico-genomic characteristics of lung squamous cell carcinoma without smoking history: A nationwide database analysis in Japan <u>Yuji Uehara</u> , NCCN - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, Japan	



15:59 - 16:06	930 - Perspectives from a 3-year review of expanded molecular profiling and tumor board-integrated clinical trial matching from a tertiary cancer centre in Singapore <u>Su Fen Ang</u>, National Cancer Centre Singapore, Singapore, Singapore
16:06 - 16:18	Invited Discussant abstracts 890, 920 and 930
16:18 - 16:25	690 - Machine learning and radiomics for predicting efficacy of Aumolertinib for EGFR mutation-positive non-small cell lung cancer: A multicenter cohort study <u>Ran Wang</u>, The First Affiliated Hospital of Anhui Medical University, Hefei, China
16:25 - 16:32	940 - Integrative Transcriptomics and Machine Learning Approach Prioritises MMP2 as a Treatment Response Associated Target for Drug Repurposing in Cervical Cancer <u>Kshreeraja Satish</u>, M. S. Ramaiah University of Applied Sciences, Bangalore, India
16:32 - 16:42	Invited Discussant abstracts 690 and 940
16:42 - 16:49	10 - Precectabart tocentecan (M9140): Initial results from the Phase 1 PROCEADE-CRC-01 dose optimization study and preclinical antitumor activity across tumor models <u>Hirokazu Shoji</u>, National Cancer Center - Tsukiji Campus, Chuo-ku, Japan
16:49 - 16:56	20 - Sacituzumab Govitecan (SG) For Chinese Patients (Pts) With Recurrent/Metastatic (R/M) Cervical Cancer (CC): Results From the EVER-132-003 Basket Study <u>Jusheng An</u>, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China
16:56 - 17:03	390 - A Phase 1b/2 update of ADG126 (an Anti-CTLA-4 Masking Antibody) Across Different Dosing Regimens in Combination with Pembrolizumab in Advanced/Metastatic MSS CRC <u>Sun Young Kim</u>, Asan Medical Center - University of Ulsan, Seoul, Republic of Korea
17:03 - 17:15	Invited Discussant abstracts 10, 20 and 390
17:15 - 17:25	Q&A



20.07.2025

08:30 - 09:45 **Type: Educational session** **Grand Ballroom 1**
Title: Therapeutic in vivo delivery of gene editing agents
Moderation: Hyun Jung Chung, Republic of Korea; Xiawei Wei, China

08:30 - 08:45 **The translational research in therapeutic tumour vaccines**
Xiawei Wei, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China

08:45 - 09:00 **Synthetic nanocarriers for in vivo gene delivery**
Ji Hoon Jeong, SKKU - Sungkyunkwan University - Natural Sciences Campus, Suwon, Republic of Korea

09:00 - 09:15 **Protein conjugate platforms for in vivo gene editing**
Hyun Jung Chung, KAIST - Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea

09:15 - 09:45 **Panel discussion and Q&A**

08:30 - 09:45 **Type: Educational session** **Grand Ballroom 4**
Title: New ADC construction and drug development
Moderation: Jayesh Desai, Australia

08:30 - 08:50 **ADCs - The next generation: Novel constructs, bispecifics and payloads**
Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, United Kingdom

08:50 - 09:10 **ADCs: Understanding the target expression, its heterogeneity and key considerations**
Jorge Reis-Filho, AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America

09:10 - 09:30 **Contemporary phase I trial design: Fit-for-purpose for ADCs?**
Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia

09:30 - 09:45 **Q&A and discussion**

09:45 - 10:15 **Type: Break** **Foyer**
Title: Coffee break

10:15 - 11:30 **Type: Special session with Industry** **Grand Ballroom 1**
Title: Hurdles in the regulatory and operational framework of early drug development in Asia
Moderation: Ashley Lakner, Switzerland

10:15 - 10:30 **Challenges in early drug development: Perspectives from an academia viewpoint**
Kenichi Nakamura, National Cancer Center, Tokyo, Japan



10:30 - 10:45 **Early drug development in China: Learnings from the past and solutions for the future**
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

10:45 - 11:00 **Challenges in early drug development in the APAC region from the regulatory point of view**
Younjoo Park, Seoul National University (SNU) - Main Campus, Seoul, Republic of Korea

11:00 - 11:30 **Panel discussion and Q&A**

10:15 - 11:30 **Type: Educational session** **Grand Ballroom 4**
Title: Use of liquid biopsy to accelerate clinical research
Moderation: Elena Garralda, Spain

10:15 - 10:30 **Liquid biopsies in phase I clinical trials**
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Australia

10:30 - 10:45 **What are the future applications of liquid biopsy in clinical research?**
Benjamin Besse, Institut Gustave Roussy, Villejuif, France

10:45 - 11:00 **Incorporating ctDNA into tumour evaluation response criteria**
Elena Garralda, Vall d'Hebron University Hospital, Barcelona, Spain

11:00 - 11:15 **Understanding host and tumour biology through liquid biopsies**
Dominic Rothwell, Cancer Research UK Manchester Institute, Manchester, United Kingdom

11:15 - 11:30 **Q&A and discussion**

11:35 - 12:05 **Type: Keynote address** **Grand Ballroom 1**
Title: Fast forward to the future: Personalised drug development for lung cancer
Moderation: Fabrice André, France

11:35 - 11:40 **Introduction to the Keynote Speaker**
Fabrice André, Gustave Roussy - Cancer Campus, Villejuif, France

11:40 - 12:05 **Fast forward to the future: Personalised drug development for lung cancer**
Tony S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, Hong Kong SAR, China

12:05 - 12:45 **Type: Break** **Foyer**
Title: Lunch

12:45 - 13:45 **Type: Industry Satellite symposium** **Grand Ballroom 4**
Title: Johnson&Johnson - Innovations in drug discovery: Insights and opportunities in the Asia Pacific
Moderation: Tony S.K. Mok, Hong Kong SAR, China



- 12:45 - 13:00 **Innovating health: The drug development pipeline explained**
John Eckardt, Johnson & Johnson Innovative Medicine, Titusville, United States of America
- 13:00 - 13:15 **From research to reality: The journey of drug development**
Jii Bum Lee, Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea
- 13:15 - 13:30 **The importance of multi-disciplinary team for drug development**
Herbert Ho Fung Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China
- 13:30 - 13:45 **Panel discussion**

14:00 - 15:30 **Type: Special session** **Grand Ballroom 1**
Title: Growing an ecosystem of biotech, pharma and drug developers in Asia
Moderation: Weng Li Yoon, China

- 14:00 - 14:20 **The biotech perspective**
Ashley Lakner, F. Hoffmann-La Roche AG, Basel, Switzerland
- 14:20 - 14:40 **The investor perspective**
Derek Yoon, Solasta Ventures, Boston, United States of America
- 14:40 - 15:00 **The physician/trialist perspective**
Tak Mak, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada
- 15:00 - 15:10 **The patient perspective**
Leslie Gilham, Breast Cancer Trials, Newcastle, Australia
- 15:10 - 15:30 **Panel discussion and Q&A**

14:00 - 15:15 **Type: Educational session** **Grand Ballroom 4**
Title: Radioligand therapeutics: Drug development and practical implementation
Moderation: Ben Tran, Australia

- 14:00 - 14:15 **Theranostics for oncologists: Current companion diagnostics and precision therapies, and future perspectives**
Grace Kong, The University of Melbourne, Parkville, Australia
- 14:15 - 14:30 **Industry considerations for developing radioligand therapeutics**
Darshan Dalal, AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America



- 14:30 - 14:45 **Setting up a theranostics centre**
Mike Sathekge, University of Pretoria, Pretoria, South Africa
- 14:45 - 15:00 **Considerations for theranostics-based first-in-human studies: A phase I trialist perspective**
Ben Tran, Peter MacCallum Cancer Centre, Melbourne, Australia
- 15:00 - 15:15 **Q&A and discussion**